drugset / Trial / NCT00284947
Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids
NaSingle-groupOpen-labelPrevention
Summary
The long-term use of calcineurin inhibitors (CNI) in patients who have received a kidney transplantation is associated with renal dysfunction and hypertension. The study will evaluate the safety and efficacy of replacing the calcineurin inhibitors by using basiliximab at monthly doses.
Timeline
- Start
- 2006-01
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Basiliximab | Monoclonal antibody | 40 mg | Intravenous |
| Background | EC-MPS | Unknown | 720 mg | Oral |
| Background | MMF | Unknown | 1 g | Oral |
| Background | Methylprednisolone | Other / unclassified | — | — |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |
| Background | Prednisone | Other / unclassified | 10 mg | Oral |
Indications
No indication recorded.